SCHEMBL2275889

SCHEMBL2275889

COC(=O)c1ccc(COc2ccccc2)cc1NC(=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.61
HPGD P15428 6/20 0.61
HSD17B10 Q99714 4/20 0.61
TSHR P16473 4/20 0.61
LMNA P02545 2/20 0.61
NPSR1 Q6W5P4 1/20 0.61
ALDH1A1 P00352 6/20 0.58
MAPT P10636 6/20 0.58
MAPK1 P28482 1/20 0.56
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
RXFP1 Q9HBX9 1/20 0.55
MAPK10 P53779 1/20 0.53
APOBEC3A P31941 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53
HTT P42858 1/20 0.53
POLB P06746 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145407 0.89 MEN1 (0.59) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL2277733 0.88 KDM4E (0.64) KDM4EHPGDHSD17B10TSHRLMNA
SCHEMBL2291513 0.82 KDM4E (0.69) KDM4EHPGDHSD17B10TSHRLMNA
SCHEMBL7710629 0.82 KDM4E (0.66) KDM4EHPGDHSD17B10TSHRLMNA
SCHEMBL2972861 0.81 HPGD (0.54) KDM4EHPGDHSD17B10TSHRLMNA
SCHEMBL2275077 0.80 KDM4E (0.66) KDM4EHPGDHSD17B10TSHRLMNA
SCHEMBL2291530 0.80 KDM4E (0.69) KDM4EHPGDHSD17B10TSHRLMNA
SCHEMBL28900358 0.80 MAPT (0.56) KDM4EHPGDHSD17B10NPSR1ALDH1A1
SCHEMBL6338190 0.80 KDM4E (0.66) KDM4EHPGDHSD17B10TSHRLMNA
SCHEMBL2274042 0.80 KDM4E (0.57) KDM4EHPGDHSD17B10LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 KDM4E 1257/4885HPGD 274/4885HSD17B10 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.